Initial results from Novavax’ COVID-19-Influenza vaccine trial were first to show feasibility of combination vaccine
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
On Apr. 20, 2022, Codiak BioSciences announced announc a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of…
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
On Apr. 14, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
On Apr. 8, 2022, Novavax announced and Serum Institute of India (SII), the world’s largest vaccine manufacturer by…
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…
On Mar. 21, 2022, in support of the Cancer Moonshot’s goal of fostering data sharing in cancer research,…
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
Our Heroes and Remembrance illustration has Maurice Ralph Hilleman and John Enders, pioneering developers of common vaccines, and…
On Nov. 17, 2021, scientists at the Centers for Disease Control and Prevention (CDC) announced they were collaborating…
On Nov. 9, 2021, Howard Hughes Medical Institute announced a program, named Codetta, that can read the genome…
On Sept. 23, 2021, Novavax with its partner, Serum Institute of India, announced a regulatory submission to the…
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
On Sept. 16, 2021, Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing…
On Sept. 14, 2021, the National Institutes of Health (NIH) announced that an international project called the COVID…
On Sept. 14, 2021, Emergent BioSolutions and Providence Therapeutics announced they have entered into a five-year contract development…
On Sept. 9, 2021, the National Institutes of Health (NIH) announced that it was providing approximately $185 million…
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…
On Sept. 7, 2021, Takeda Pharmaceutical announced the Government of Japan’s Ministry of Health, Labour and Welfare purchase…
On Aug. 27, 2021, the National Institutes of Health announced that it had begun a clinical trial to…
On Aug. 18, 2021, the final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO)…
On Aug. 16, 2021, scientists at the National Institutes of Health (NIH) announced they had developed a new…
On Aug. 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved WELIREG, an…
On Aug. 11, 2021, the National Institutes of Health (NIH) announced that one dose of a new monoclonal…
On Aug. 6, 2021, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Nexviazyme® (avalglucosidase alfa-ngpt) for the…
On Aug. 5, 2021, an international team of researchers announced that a mutation in a single gene appeared…
On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
On Jul. 30, 2021, Regeneron announced that the U.S. Food and Drug Administration (FDA) had updated the Emergency…